info@epichembio.eu + 34 986 812 316

Campiani Group, NatSynDrugs. Drug Discovery and Development

campiani@unisi.it
www.natsyndrugs.org
Address
University of Siena, NatSynDrugs, Via Aldo Moro 2. 53100 Siena
Italy
Keywords

Rare diseases, HDACs, cancer, neurodegenerative disorders, parasitic diseases

Models

Target selection and validation, rational design of innovative drugs, discovery of new synthetic methodologies and general strategies for synthesis, study of important structure-function relationships and drug repurposing approaches.

Techniques

Organic synthesis, peptide synthesis, stereoselective synthesis, compound analysis and characterization (NMR, HPLC, ESI-MS, GC-MS, fluorescence), bioinformatics, molecular modelling, structure-based and ligand-based drug design. Natural compounds.

Collaborations outside COST

Prof. Daniela Zisterer, Trinity College, IRL Prof. Arun K Ghosh, Purdue University, US Prof. Mauro Maccarrone, University Tor Vergata, IT Prof. Vincenzo di Marzo, CNR-Napoli, IT

Short description of ongoing research projects

Investigation related to COST Action: HDAC inhibitors. This activity already led to the discovery of novel chemical scaffold for achieving selective HDAC6 inhibition. The identified compounds demonstrated promising antitumor profile (haematological and brain tumors). Moreover, the most selective inhibitors are currently being explored as potential therapeutic in rare and neurodegenerative diseases. Investigation of the role of HDAC in rare diseases and parasitic diseases. Repositioning approaches in rare diseases Development of Anticancer drugs.

Publications
  1. Brindisi, M.; Cavella, C.; Brogi, S.; Nebbioso, A.; Senger, J.; Maramai, S.; Ciotta, A.; Iside, C.; Butini, S.; Lamponi, S.; Novellino, E.; Altucci, L.; Jung, M.; Campiani, G.; Gemma, S. Phenylpyrrole-based HDAC inhibitors: synthesis, molecular modeling and biological studies. Fut. Med. Chem. 2016, 8, 1573-87.
  2. Brindisi M, Maramai S, Gemma S, Brogi S, Grillo A, Di Cesare Mannelli L, Gabellieri E, Lamponi S, Saponara S, Gorelli B, Tedesco D, Bonfiglio T, Landry C, Jung KM, Armirotti A, Luongo L, Ligresti A, Piscitelli F, Bertucci C, Dehouck MP, Campiani G, Maione S, Ghelardini C, Pittaluga A, Piomelli D, Di Marzo V, Butini S. Development and Pharmacological Characterization of Selective Blockers of 2-Arachidonoyl Glycerol Degradation with Efficacy in Rodent Models of Multiple Sclerosis and Pain. J Med Chem. 2016 59 (6), 2612-2632.
  3. Brindisi M, Butini S, Franceschini S, Brogi S, Trotta F, Ros S, Cagnotto A, Salmona M, Casagni A, Andreassi M, Saponara S, Gorelli B, Weikop P, Mikkelsen JD, Scheel-Kruger J, Sandager-Nielsen K, Novellino E, Campiani G, Gemma S. Targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors for developing effective antipsychotics: synthesis, biological characterization, and behavioral studies. J Med Chem. 2014 57 (22), 9578-9597.
  4. McElligott AM, Maginn EN, Greene LM, McGuckin S, Hayat A, Browne PV, Butini S, Campiani G, Catherwood MA, Vandenberghe E, Williams DC, Zisterer DM, Lawler M. The novel tubulin-targeting agent pyrrolo-1,5-benzoxazepine-15 induces apoptosis in poor prognostic subgroups of chronic lymphocytic leukemia. Cancer Res. 2009, 69(21), 8366-8375.
  5. Ferlini, C.; Cicchillitti, L.; Raspaglio, G.; Bartollino, S.; Cimitan, S.; Bertucci, C.; Mozzetti, S.; Gallo, D.; Persico, M.; Fattorusso, C.; Campiani, G.; Scambia, G., Paclitaxel Directly Binds to Bcl-2 and Functionally Mimics Activity of Nur77. Cancer Res. 2009, 69, 6906-6914.
Other activities of potential interest to others

Target identification, validation and bioinformatics approaches to rare brain and pulmonary diseases, and parasitic diseases CADD for different central and peripheral pathologies.


Cost UE